Education
About Us
Working with TipRanks
Follow Us
Oryzon Genomics SA (ES:ORY)
BME:ORY
ORY Stock Chart & Stats
€3.22
€0.02(1.34%)
At close: 4:00 PM EST
€3.22
€0.02(1.34%)
Day’s Range― - ―
52-Week Range€2.43 - €4.02
Previous CloseN/A
Volume6.85K
Average Volume (3M)1.68M
Market Cap
€213.69M
Enterprise Value€196.68M
Total Cash (Recent Filing)€31.11M
Total Debt (Recent Filing)€13.73M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
May 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio-7.53
Price to Book (P/B)1.04
Price to Sales (P/S)12.25
P/FCF Ratio-6.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€3.00M
Bulls Say, Bears Say
Bulls Say
Strong Equity PositionA high equity ratio provides a durable capital buffer against clinical and development setbacks, enabling the company to sustain R&D spending and absorb operating losses longer than peers with weaker balance sheets. This stability supports long-term program continuity and partner confidence.
High Gross MarginsSustained high gross margins for small-molecule therapeutics indicate scalable unit economics if programs reach commercialization. This margin profile can fund downstream activities and improve long-term profitability once development costs taper and products generate recurring revenues.
Focused Epigenetics PipelineSpecialization in epigenetics creates a clear scientific niche and potential competitive advantage, concentrating expertise and IP. Clinical-stage assets reduce early-stage scientific risk relative to discovery-only peers and make the company more attractive for partnerships or licensing with strategic pharma players.
Bears Say
Consistent Net LossesOngoing net losses and negative operating cash flow erode reserves and lengthen reliance on external capital. Over the medium term this increases dilution risk for shareholders, constrains discretionary investment, and raises execution risk if fundraising conditions tighten.
Rising LeverageAn uptick in leverage reduces financial flexibility and raises fixed obligations, which can crowd out R&D spending or force cost cutting if revenues remain limited. For a clinical-stage biotech, higher debt heightens downside risk from trial delays or failures.
Reliance On External FundingPositive financing cash flows alongside persistent negative free cash flow signal ongoing dependence on capital markets. Recurrent fundraising can dilute existing holders and create execution uncertainty if access to capital weakens, impacting long-term program continuity.
Oryzon Genomics SA News
ORY FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €2.43 and its highest was €4.02 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €213.69M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is May 18, 2026 which is in 74 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Feb 27, 2026. The company reported -€0.02 earnings per share for the quarter, beating the consensus estimate of -€0.034 by €0.014.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.04.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.02 in its last earnings report, beating expectations of -€0.034. Following the earnings report the stock price went down -2.484%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ES:ORY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Technical Analysis
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
ADL Bionatur Solutions SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---